Human VIP-α: A long-acting, biocompatible and biodegradable peptide nanomedicine for essential hypertension
- 30 September 2006
- journal article
- Published by Elsevier BV in Peptides
- Vol. 27 (9), 2271-2275
- https://doi.org/10.1016/j.peptides.2006.03.003
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Hypertension, stroke, and endotheliumCurrent Hypertension Reports, 2005
- The Conduction of Dilation along an Arteriole Is Diminished in the Cremaster Muscle of Hypertensive HamstersJournal of Vascular Research, 2004
- Vasorelaxations Induced by Calcitonin Gene–related Peptide, Vasoactive Intestinal Peptide, and Acetylcholine in Aortic Rings of Endothelial and Inducible Nitric Oxide Synthase–Knockout MiceJournal of Cardiovascular Pharmacology, 2003
- Vascular response to stress in health and diseaseMetabolism, 2002
- Vasoactive intestinal peptide: cardiovascular effectsCardiovascular Research, 2001
- Surface-active properties of vasoactive intestinal peptide☆Peptides, 2000
- A novel formulation of VIP in sterically stabilized micelles amplifies vasodilation in vivo.Pharmaceutical Research, 1999
- Partitioning of vasoactive intestinal polypeptide into lipid bilayersBiochimica et Biophysica Acta (BBA) - Biomembranes, 1994
- Action of pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal polypeptide on the rat vascular system: effects on blood pressure and receptor bindingJournal of Endocrinology, 1991
- Effects of arterial pressure on endothelial transport of macromoleculesBiorheology, 1984